Upstream Bio (UPB) Q2 R&D Soars 169%

Upstream Bio (UPB 8.32%), a biotechnology company developing new therapies for respiratory diseases, released its second quarter 2025 results on August 6, 2025. The main headline was rapid advancement in clinical trials for its lead drug candidate, verekitug, with major enrollment milestones hit in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Revenue (GAAP) was $0.9 million for Q2 2025, above the $0.69 million estimate. Year on year, the company's investment in research and developme ...